|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Discussion on Induan-Olenekian Boundary in Chaohu, Anhui Province, China显示文摘This paper proposes a scheme for the definition of the Lower Triassic Induan Olenekian boundary (IOB) based on investigation of sections in Chaohu, Anhui Province, China as well as data accumulated from other studies elsewhere. The conodont Neospathodus waageni is suggested as the index fossil of the boundary. According to the FAD of N. waageni , the IOB is at the base of bed 25 2 of the West Pingdingshan Section in Chaohu, 42.19 m above the Permian Triassic boundary, and it is slightly higher than the base of the Flemingites Euflemingites Ammonoid Zone at the section. | Zhao Laishi Tong Jinnan Zuo Jingxun Ming Houli China University of Geosciences, Wuhan 430074 | 2002 | Journal of China University of Geosciences2002，13，2： | 7 |
| 2 | Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies:a phase I clinical study显示文摘Chimeric antigen receptor(CAR)-T cell therapy against T cell malignancies faces major challenges including fratricide between CAR-T cells and product contamination from the blasts.Allogeneic CAR-T cells,generated from healthy donor T cells,can provide ready-to-use,blast-free therapeutic products,but their application could be complicated by graft-versus-host disease(GvHD)and host rejection.Here we developed healthy donor-derived,CD7-targeting CAR-T cells(RD13-01)with genetic modifications to resist fratricide,GvHD and allogeneic rejection,as well as to potentiate antitumor function.A phase I clinical trial(NCT04538599)was conducted with twelve patients recruited(eleven with T cell leukemia/lymphoma,and one with CD7-expressing acute myeloid leukemia).All patients achieved pre-set end points and eleven proceeded to efficacy evaluation.No dose-limiting toxicity,GvHD,immune effector cell-associated neurotoxicity or severe cytokine release syndrome(grade≥3)were observed.28 days post infusion,81.8%of patients(9/11)showed objective responses and the complete response rate was 63.6%(7/11,including the patient with AML).3 of the responding patients were bridged to allogeneic hematopoietic stem cell transplantation.With a median follow-up of 10.5 months,4 patients remained in complete remission.Cytomegalovirus(CMV)and/or Epstein-Barr virus(EBV)reactivation was observed in several patients,and one died from EBV-associated diffuse large B-cell lymphoma(DLBCL).Expansion of CD7-negative normal T cells was detected post infusion.In summary,we present the first report of a Phase I clinical trial using healthy donor-derived CD7-targeting allogeneic CAR-T cells to treat CD7^(+)hematological malignancies.Our results demonstrated the encouraging safety and efficacy profiles of the RD13-01 allogeneic CAR-T cells for CD7^(+)tumors. | Yongxian Hu Yali Zhou Mingming Zhang Houli Zhao Guoqing Wei Wengang Ge Qu Cui Qitian Mu Gong Chen Lu Han Tingting Guo Jiazhen Cui Xiaoyan Jiang Xiujun Zheng Shuhui Yu Xiaolong Li Xingwang Zhang Mingxi Chen Xiuju Li Ming Gao Kang Wang Cheng Zu Hao Zhang Xiaohong He Yanbin Wang Dongrui Wang Jiangtao Ren He Huang | 2022 | Cell Research2022，32，11： | 2 |
| 3 | Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles显示文摘 | HouLi Li XiaoBin Zhao YuKun Ma GuangXi Zhai LingBing Li HongXiang Lou | 2008 | Journal of Controlled Release2008，，3： | 1 |
| 4 | Immunomodulatory hybrid bio-nanovesicle for self-promoted photodynamic therapy显示文摘Thylakoid(Tk)membranes are of unique superiority in photodynamic therapy(PDT)because they not only carry abundant chlorophylls containing photosensitizer porphyrin but also can produce O_(2).However,the current therapeutic performance of Tk is dramatically limited because of their poor tumor targeting and inefficient O_(2) production.Here,we report an immunomodulatory bio-nanovesicle of Tk membranes fused with M1 macrophage-derived extracellular vesicles(M1 EV)for efficient PDT of tumors.The hybrid nanovesicle Tk@M1 was prepared by squeezing the Tk membranes of spinach with M1 EV.The systemic study confirmed that Tk@M1 can not only actively accumulate in tumors but also effectively regulate the inactive immune microenvironment of tumors.Such activated'hot'tumors significantly enhance the PDT efficacy of Tk@M1 attributed to the increased O_(2) from catalase catalyzed decomposition of augmented H_(2)O_(2),providing a novel idea about constructing natural systems for effective tumor treatment. | Houli Liu Yao Lei Weidong Nie Helin Zhao Yuzhu Wu Liping Zuo Guanghao Wu Ruili Yang Hai-Yan Xie | 2022 | Nano Research2022，15，5： | 1 |
| 5 | Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles显示文摘 | Li Houli Zhao Xiaobin Ma Yukun | 2009 | J Control Release2009，133，3： | 1 |
| 6 | A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma显示文摘The combination of the immunotherapy(i.e.,the use of monoclonal antibodies)and the conventional chemotherapy increases the long-term survival of patients with lymphoma.However,for patients with relapsed or treatment-resistant lymphoma,a novel treatment approach is urgently needed.Chimeric antigen receptor T(CAR-T)cells were introduced as a treatment for these patients.Based on recent clinical data,approximately 50%of patients with relapsed or refractory B-cell lymphoma achieved complete remission after receiving the CD19 CAR-T cell therapy.Moreover,clinical data revealed that some patients remained in remission for more than two years after the CAR-T cell therapy.Other than the CD19-targeted CAR-T,the novel target antigens,such as CD20,CD22,CD30,and CD37,which were greatly expressed on lymphoma cells,were studied under preclinical and clinical evaluations for use in the treatment of lymphoma.Nonetheless,the CAR-T therapy was usually associated with potentially lethal adverse effects,such as the cytokine release syndrome and the neurotoxicity.Therefore,optimizing the structure of CAR,creating new drugs,and combining CAR-T cell therapy with stem cell transplantation are potential solutions to increase the effectiveness of treatment and reduce the toxicity in patients with lymphoma after the CAR-T cell therapy. | Houli Zhao Yiyun Wang Elaine Tan Su Yin Kui Zhao Yongxian Hu He Huang | 2020 | Frontiers of Medicine2020，14，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员